Challenges Involved in Incorporating Personalised Treatment Plan as Routine Care of Patients with Diabetes.

monogenic forms of diabetes personalised treatment type 1 diabetes type 2 diabetes

Journal

Pharmacogenomics and personalized medicine
ISSN: 1178-7066
Titre abrégé: Pharmgenomics Pers Med
Pays: New Zealand
ID NLM: 101514107

Informations de publication

Date de publication:
2021
Historique:
received: 24 12 2020
accepted: 22 02 2021
entrez: 24 3 2021
pubmed: 25 3 2021
medline: 25 3 2021
Statut: epublish

Résumé

Diabetes is a heterogenous disorder, and patients with this disorder vary considerably in their clinical presentation, response to therapy and risk of complications. Expanding knowledge about the pathophysiology of various forms of diabetes has raised the possibility that diagnostic and therapeutic modalities can be tailored to the individual patient in a personalized manner. The recent publication of a Consensus Statement on precision diabetes care underlines the major strides made in this field in the recent past. However, while personalized diabetes care has the potential to significantly improve outcomes in patients with diabetes in a safe and cost-effective manner, its wider application presents several challenges, especially in resource-strained settings. These challenges pertain equally to precision diagnostics, precision therapeutics and precision monitoring. This article discusses some of the important challenges that care providers are likely to face in applying the personalized approach in caring for their patients with diabetes, in the context of diagnosis and management of type 1 diabetes, type 2 diabetes and monogenic forms of diabetes. Suggestions are also presented for overcoming some of these challenges.

Identifiants

pubmed: 33758531
doi: 10.2147/PGPM.S271582
pii: 271582
pmc: PMC7981142
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

327-333

Informations de copyright

© 2021 Unnikrishnan et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

Diabetologia. 2020 Jun;63(6):1103-1109
pubmed: 32236731
Diabetologia. 2017 Sep;60(9):1648-1655
pubmed: 28770331
Diabetes Care. 2020 Aug;43(8):1948-1957
pubmed: 33534728
Diabetes Care. 2017 Nov;40(11):1425-1432
pubmed: 28801473
BMJ Open Diabetes Res Care. 2020 Jul;8(1):
pubmed: 32699108
PLoS One. 2016 Aug 16;11(8):e0160024
pubmed: 27529339
Indian J Med Res. 2014 Sep;140(3):356-60
pubmed: 25366202
Diabetes. 2009 Apr;58(4):773-95
pubmed: 19336687
Diabetes Care. 2020 Jul;43(7):1617-1635
pubmed: 32561617
BMJ Open Diabetes Res Care. 2020 Aug;8(1):
pubmed: 32816869
Expert Opin Pharmacother. 2020 Sep;21(13):1565-1578
pubmed: 32521177
J Diabetes Complications. 2021 Jan;35(1):107640
pubmed: 32763092
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124
pubmed: 33298420
Nat Clin Pract Endocrinol Metab. 2008 Apr;4(4):200-13
pubmed: 18301398
Endocr Metab Immune Disord Drug Targets. 2019;19(2):121-127
pubmed: 30173655
Indian J Med Res. 2018 Nov;148(5):472-475
pubmed: 30666973
Lancet Diabetes Endocrinol. 2019 Sep;7(9):684-694
pubmed: 31345776
Diabetes Care. 2016 Feb;39(2):179-86
pubmed: 26798148
Lancet Diabetes Endocrinol. 2019 Jun;7(6):442-451
pubmed: 31047901
Diabetes. 1975 Jan;24(1):44-53
pubmed: 1122063
Lancet Diabetes Endocrinol. 2019 Jan;7(1):9-11
pubmed: 30577891
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
J Clin Invest. 2020 Jan 2;130(1):14-16
pubmed: 31815736

Auteurs

Ranjit Unnikrishnan (R)

Department of Diabetology, Dr. Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Chennai, India.

Venkatesan Radha (V)

Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, India.

Viswanathan Mohan (V)

Department of Diabetology, Dr. Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Chennai, India.

Classifications MeSH